NEW DELHI—Gilead Sciences Inc. said Monday it has authorized several generic drug companies in India to sell its $1,000-a-day hepatitis C pill for a fraction of the price in developing countries like Honduras, Vietnam and South Africa.. The California-based biotechnology company said it signed licensing deals with seven generic pharmaceutical companies that make drugs in India, including Ranbaxy Laboratories Ltd., Cipla Ltd. and Pennsylvania-based Mylan Inc., to sell generic versions of Sovaldi in 91 developing countries. 